)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Evotec
Evotec (EVT) investor relations material
Evotec Morgan Stanley 24th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Morgan Stanley 24th Annual Global Healthcare Conference summary16 Sep, 2026
Initial reflections and organizational strengths
Scientific expertise and breadth of knowledge are key differentiators, offering a wide range of services.
The company's story and value proposition are complex, requiring clearer market communication.
An outside-in perspective enables objective questioning and process simplification.
Transparent internal dialogue is used to drive future performance.
Market environment and customer sentiment
Sector funding is improving, especially in later-stage pipeline investments, boosting market confidence.
Commercial indicators, including year-on-year sales, show positive momentum.
Customers are cautiously optimistic, focusing investments for maximum returns.
Horizon transformation program
Horizon targets €75 million in savings, with 20–30% impact expected in 2026.
Initiatives include site consolidation, centers of expertise, commercial investment, and process simplification.
The program aims to create a stable, growth-oriented platform beyond cost savings.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Evotec
- Revenue and profitability declined sharply, with losses deepening and guidance lowered for 2026.EVT
Q2 2026 - Accelerating growth with innovation, cost savings, and a high-value asset pipeline.EVTCompany presentation
- 2026 outlook cut as partnership delays weigh, but core business segments show strong momentum.EVTQ2 2026 TU
- Annual meeting to elect Trustees, review governance, and address audit and risk oversight.EVTProxy filing
- Operational excellence, pipeline growth, and asset-light strategy drive sustainable value creation.EVTCompany presentation
- Biologics growth, cost savings, and Horizon transformation drive high-end 2025 results.EVTQ4 2025
- Biologics growth and €40m cost savings offset R&D decline, supporting 2024 guidance.EVTQ3 2024
- Revenue up 2%, but losses deepened and restructuring accelerated in H1 2024.EVTQ2 2024
- Revenue fell 4% but Biologics grew 10–11%, with guidance and cost savings reaffirmed.EVTQ1 2025
Next Evotec earnings date
Q3 20265 Nov, 2026
Evotec
Next Evotec earnings date
Q3 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Evotec SE is a biotechnology company specializing in drug discovery and development services. The company collaborates with pharmaceutical and biotech firms, academic institutions, and research organizations to identify and develop therapeutic candidates across various disease areas, including neurology, oncology, and metabolic disorders. The company is headquartered in Hamburg, Germany, and its shares are listed on the FSE (Frankfurt Stock Exchange).